Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 9/20 | 0.70 |
| ▸ | THRA | P10827 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | TTR | P02766 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reverse Triiodothyronine SCHEMBL29354492 | 1.00 | MEN1 (1.00) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL93386 | 1.00 | MEN1 (1.00) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reverse Triiodothyronine SCHEMBL93385 | 1.00 | MEN1 (1.00) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reverse Triiodothyronine SCHEMBL2317251 | 0.99 | MEN1 (0.97) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL30812344 | 0.93 | MEN1 (0.86) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL30096343 | 0.92 | MEN1 (0.84) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL14576176 | 0.91 | MEN1 (0.84) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL14576177 | 0.91 | MEN1 (0.84) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL14587190 | 0.90 | MEN1 (0.82) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Rathyronine SCHEMBL10592340 | 0.88 | THRB (0.78) | MEN1KMT2APPARGNR1I2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733383-A1 | CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME | Japan Institute for Health Security (JP) | 2026-04-29 | — | — | EP | claimed |
| WO-2024262610-A1 | CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME | 国立研究開発法人国立国際医療研究センター | 2024-12-26 | — | — | WO | claimed |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| US-20200222348-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2020-07-16 | — | — | US | claimed |
| EP-3621602-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | Musli Thyropeutics Ltd. (IL) | 2020-03-18 | — | — | EP | claimed |
| WO-2018207171-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2018-11-15 | — | — | WO | claimed |
| US-9328331-B2 | Compositions and methods for promoting beta cell maturity | JOSLIN DIABETES CENTER, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20120141436-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-03-17 | — | — | US | claimed |
| WO-2010135639-A2 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| US-20060172415-A1 | Oligodendrocyte precursor cells and method of obtaining and culturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-03 | — | — | US | claimed |
| EP-1646711-A2 | OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF OBTAINING AND CULTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-19 | — | — | EP | claimed |
| EP-0982399-B1 | Thyroid hormone transporters, agonists and antagonists thereof | STICHTING TOT BEVORDERING VAN (NL) | 2005-10-26 | — | — | EP | claimed |
| WO-2005007797-A2 | OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF OBTAINING AND CULTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (US) | 2005-01-27 | — | — | WO | claimed |
| EP-0831769-B1 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | KAROBIO AB (SE) | 2003-10-15 | — | — | EP | claimed |
| WO-2001035902-A9 | STABILIZED THYROXINE COMPOUNDS | LOTUS BIOCHEMICAL CORP (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001035902-A2 | STABILIZED THYROXINE COMPOUNDS | LOTUS BIOCHEMICAL CORPORATION (US) | 2001-05-25 | — | — | WO | claimed |
| EP-0467466-A1 | Method for the purification of immunoreactive labeled thyroxine conjugates | EASTMAN KODAK COMPANY (US) | 1992-01-22 | — | — | EP | claimed |
| EP-0093653-B1 | PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL | SPIRAL Société à responsabilité limitée dite : (FR) | 1985-07-10 | — | — | EP | claimed |
| US-4490221-A | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential | SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) | 1984-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | IAPP, ALPG, PNLIP | MEN1 4231/4885KMT2A 4248/4885PPARG 1073/4885 |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | TPO, TSHR, THRA | MEN1 301/4885KMT2A 4327/4885PPARG 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.